Author | Illarramendi Rojas, Ximena | |
Author | Oliveira, Maria Leide Wand del Rey de | |
Author | Sales, Ana Maria | |
Author | Nery, José Augusto da Costa | |
Author | Sarno, Euzenir Nunes | |
Access date | 2015-09-21T17:25:45Z | |
Available date | 2015-09-21T17:25:45Z | |
Document date | 2013 | pt_BR |
Citation | ILLARRAMENDI ROJAS, Ximena et al. Considerations on clinical trials of leprosy treatment: need of novel drug combinations. Clin. Invest., v.3, n.7, p.617-635, 2013. | pt_BR |
URI | https://www.arca.fiocruz.br/handle/icict/11778 | |
Language | eng | pt_BR |
Publisher | Future Science Group | pt_BR |
Rights | open access | pt_BR |
Subject in Portuguese | Resistência | pt_BR |
Title | Considerations on clinical trials of leprosy treatment: need of novel drug combinations | pt_BR |
Type | Article | pt_BR |
DOI | 10.4155/CLI.13.52 | pt_BR |
Abstract | Considering that after 30 years of using multidrug therapy (MDT), leprosy
eradication has still not been achieved, leprosy treatment must remain on
the drug discovery agenda. Due to the complexities inherent in leprosy
disease and the many methodological issues involved in clinical trials,
the task of translating the bench findings into clinical practice has been
arduous. While the effectiveness of reducing the currently recommended
MDT remains controversial, a number of highly bactericidal antibiotics
and immune-modulatory drugs have emerged as prospective candidates
to improve patient adherence and quality of life, reduce adverse effects
and prevent resistance. To replace the standard WHO-MDT, the new
combination must be the shortest, simplest and, consequently, most
affordable treatment possible. | en |
Affilliation | Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Hanseníase. Rio de Janeiro, RJ, Brasil. | pt_BR |
Affilliation | Universidade Federal do Rio de Janeiro. Departamento de Dermatologia. Rio de Janeiro, RJ, Brasil. | pt_BR |
Affilliation | Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Hanseníase. Rio de Janeiro, RJ, Brasil. | pt_BR |
Affilliation | Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Hanseníase. Rio de Janeiro, RJ, Brasil. | pt_BR |
Affilliation | Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Hanseníase. Rio de Janeiro, RJ, Brasil. | pt_BR |
Subject | Clinical trial | pt_BR |
Subject | Drug combination | pt_BR |
Subject | Leprosy | pt_BR |
Subject | Multidrug therapy | pt_BR |
Subject | Relapse | pt_BR |
Subject | Resistance | pt_BR |
Subject | Surrogate end point | pt_BR |
Subject | Treatment | pt_BR |
DeCS | Hanseníase | pt_BR |
DeCS | Ensaio Clínico | pt_BR |
DeCS | Múltiplos Medicamentos | pt_BR |
DeCS | Recidiva | pt_BR |